Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MADRID, Spain and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
-
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
-
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
-
Encouraging clinical results from TACTI-002 and INSIGHT-004 trials of eftilagimod alphacompleted recruitment for Stage 1 of Part B in TACTI-002 StudyGranted United States patent relating to...
-
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancerFirst results from Revocan are expected early 2021 PARIS, Oct. 21, 2020 ...
-
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test...
-
GUANGZHOU, China, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing...
-
New data reinforces Immunoscore clinical utility in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
-
NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN SALT LAKE CITY, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:...
-
NEW YORK and VIENNA, Austria, Oct. 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers...